We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Advertisement
Product
Advertisement
bit.bio logo

ioMicroglia™ – consistent iPSC-derived microglia, ready in 10 days!

ioMicroglia™ – consistent iPSC-derived microglia, ready in 10 days!


Advertisement
bit.bio logo

ioMicroglia are cryopreserved human iPSC-derived microglia powered by bit.bio’s opti-ox™ precision reprogramming technology, built so scientists no longer have to battle with long differentiation protocols that produce inconsistent cell populations.

In just 10 days post-revival, ioMicroglia show:

  • a typical ramified morphology
  • consistent and defined cell populations
  • expression of key phenotypic markers (TMEM119, P2RY12, IBA1, CX3CR1, CD11b, CD45, and CD14)
  • a transcriptomic signature with high equivalence to primary adult and foetal microglia
  • typical microglial functions including phagocytosis (amyloid beta (1-42), apoptotic cells and bacteria) and proinflammatory cytokine secretion (IL-6 and TNFα), upon stimulation
  • co-culture compatibility with bit.bio ioGlutamatergic Neurons, whilst maintaining their function

ioMicroglia are now available for early access testers. Register your interest today.


Product Specifications
Marker expression TMEM119, P2RY12, IBA1
Vial size 1.5 million viable cells
Shipping format Cryopreserved
Viability >80%
Seeding density 37,000-39,500 cells/cm2
Seeding compatibility 6, 12, 24 and 96 well plates
Validated functions Phagocytosis, cytokine secretion, co-cultures with neurons
Price Available on request
About bit.bio
bit.bio is an award-winning human synthetic biology company based in Cambridge, UK. Our cell identity coding platform has the ability to create any human cell type and to manufacture it at scale with precision and consistency. Having access to human cells has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease and form the basis for a new generation of cell and tissue therapies. It will enable us to realise our vision: biomedical innovation and a new generation of cures through precision reprogrammed human cells. The cell identity coding platform consists of three core parts: our discovery platform which identifies the precise code that defines cell fate; our precision cellular reprogramming technology - opti-ox - that deterministically reprograms stem cells into any cell type; and our world leading expertise in stem cell reprogramming, manufacturing and clinical translation. Using our platform, we have already launched multiple wild type and disease model cells under our ioCells™ brand for research and drug discovery. The platform also means we can offer custom partnership capabilities. And we are currently building our own, in-house cell therapy pipeline using our platform.